March 1, 2020 Issue of JAMA Oncology (2024)

Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades

Jennifer M.Yeh,PhD; Zachary J.Ward,MPH; AeyshaChaudhry,MSc; et al.

free access

JAMA Oncol. 2020;6(3):350-357. doi:10.1001/jamaoncol.2019.5582

This decision analytical model–based study uses data from the Childhood Cancer Survivor Study to project long-term survival and assess whether life expectancy will improve among adult survivors of childhood cancer who were treated in more recent decades.

• Editorial

  Minding the Gap for Survivors of Childhood Cancer

  Stephanie M.Smith,MD, MPH; Michael P.Link,MD; Karen E.Effinger,MD, MS

  JAMA Oncol

Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

ShuhongShen,MD, PhD; XiaojuanChen,MD, PhD; JiaoyangCai,MD, PhD; et al.

free access

JAMA Oncol. 2020;6(3):358-366. doi:10.1001/jamaoncol.2019.5868

This phase 3 randomized clinical trial assesses whether dasatinib given at 80 mg/m² is more effective than imatinib mesylate at 300 mg/m² to improve event-free survival in children with Philadelphia chromosome–positive acute lymphoblastic leukemia.

• Editorial

  Optimizing Targeted Therapy for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

  Karen R.Rabin,MD, PhD

  JAMA Oncol

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial

Joseph A.Sparano,MD; Robert J.Gray,PhD; Della F.Makower,MD; et al.

free access

JAMA Oncol. 2020;6(3):367-374. doi:10.1001/jamaoncol.2019.4794

This secondary anaysis of the TAILORx randomized clinical trial describes clinical outcomes for women with a high 21-gene recurrence score who received adjuvant chemotherapy plus endocrine therapy, a population expected to have a high distant recurrence rate with endocrine therapy alone.

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis

JianchunDuan,MD; LonggangCui,PhD; XiaochenZhao,MD; et al.

free access

JAMA Oncol. 2020;6(3):375-384. doi:10.1001/jamaoncol.2019.5367

This systematic review and meta-analysis of randomized clinical trials examines use of programmed cell death 1 (PD-1) vs programmed cell death–ligand 1 (PD-L1) treatment in patients with cancer.

Association of Insurance Status and Racial Disparities With the Detection of Early-Stage Breast Cancer

Naomi Y.Ko,MD, MPH, AM; SusanHong,MD, MPH; Robert A.Winn,MD; et al.

free access

JAMA Oncol. 2020;6(3):385-392. doi:10.1001/jamaoncol.2019.5672

This cross-sectional study uses data from the Surveillance, Epidemiology, and End Results Program to examine the extent to which insurance is associated with access to timely breast cancer diagnosis and breast cancer stage differences among a large, diverse population of US patients with breast cancer.

Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada

JillFurzer,MA; SumitGupta,MD, PhD; Paul C.Nathan,MD, MSc; et al.

free access

JAMA Oncol. 2020;6(3):393-401. doi:10.1001/jamaoncol.2019.5909

This cost-utility analysis assesses the value of tisagenlecleucel compared with current standard care for tisagenlecleucel-eligible pediatric patients with acute lymphoblastic leukemia.

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial

Ciara M.Kelly,MBBCh, BAO, MD; Cristina R.Antonescu,MD; TimothyBowler,MD; et al.

free access

JAMA Oncol. 2020;6(3):402-408. doi:10.1001/jamaoncol.2019.6152

This phase 2 clinical trial examines whether talimogene laherparepvec in combination with pembrolizumab is associated with increased tumor-infiltrating lymphocyte infiltration and programmed death-ligand 1 expression, and thus with increased antitumor activity in patients with locally advanced or metastatic sarcoma.

The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials

Mohamad BassamSonbol,MD; Luke J.Mountjoy,DO; BelalFirwana,MD; et al.

free access online only has audio

JAMA Oncol. 2020;6(3):e194489. doi:10.1001/jamaoncol.2019.4489

This systematic review and network meta-analysis of randomized clinical trials evaluates the comparative effectiveness of different treatment strategies in metastatic colorectal cancer.

• Audio Author Interview: The Role of Maintenance Strategies in Metastatic Colorectal Cancer

Analysis of Price Transparency via National Cancer Institute–Designated Cancer Centers’ Chargemasters for Prostate Cancer Radiation Therapy

AnkitAgarwal,MD, MBA; AnupriyaDayal,MD; Sheetal M.Kircher,MD; et al.

free access has audio

JAMA Oncol. 2020;6(3):409-412. doi:10.1001/jamaoncol.2019.5690

This economic evaluation of prostate cancer radiation therapy costs at National Cancer Institute–designated cancer centers assesses the value of the price transparency mandate of the US Centers for Medicare & Medicaid Services in allowing patients with prostate cancer to shop by price for radiation treatment.

• Audio Author Interview: Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial

ZhiminShao,MD; DaPang,MD; HongjianYang,MD; et al.

free access online only

JAMA Oncol. 2020;6(3):e193692. doi:10.1001/jamaoncol.2019.3692

This phase 3 randomized clinical trial compares the efficacy, safety, and tolerability of adding pertuzumab to trastuzumab and docetaxel vs placebo, trastuzumab, and docetaxel in Asian patients with ERBB2-positive early or locally advanced breast cancer.

Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials

Thomas M.Atkinson,PhD; Amylou C.Dueck,PhD; Daniel V.Satele; et al.

free access

JAMA Oncol. 2020;6(3):437-439. doi:10.1001/jamaoncol.2019.5566

This retrospective analysis of clinical trials compares clinician reporting of adverse events and patient reporting of analogous symptoms.

The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in Oncology

IsmailJatoi,MD, PhD; Mitchell H.Gail,MD, PhD

JAMA Oncol. 2020;6(3):420-424. doi:10.1001/jamaoncol.2019.5361

This article makes a case for inclusion of secondary end points in noninferiority trials in oncology and provides mathematical examples of how such noninferiority might be calculated in such cases.

Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review

FrancescoMaura,MD; NiccolòBolli,MD, PhD; Even H.Rustad,MD, PhD; et al.

JAMA Oncol. 2020;6(3):425-432. doi:10.1001/jamaoncol.2019.4659

This review summarizes current clinical challenges and discusses available models for risk stratification in the context of smoldering multiple myeloma.

Progressive Dyspnea in a Woman With Genital Skin Lesions

HiroyukiTeruya,MD; MitsuruMukaigawara,MD; KazuhitoHirata,MD

JAMA Oncol. 2020;6(3):433-434. doi:10.1001/jamaoncol.2019.5863

An 82-year-old woman presents with dyspnea on exertion, lesions on her genital area, mild right atrial and ventricular dilatation, and severe tricuspid regurgitation. What is your diagnosis?

Can Cannabis Cure Cancer?

Donald I.Abrams,MD; ManuelGuzmán,PhD

JAMA Oncol. 2020;6(3):323-324. doi:10.1001/jamaoncol.2019.5983

This Viewpoint discusses whether cannabis has any direct antitumor activity.

How Is Money Changing Medicine?—Venture Capital Investment in Oncology

Kevin B.Huang,BS; Vinod E.Nambudiri,MD, MBA

JAMA Oncol. 2020;6(3):325-326. doi:10.1001/jamaoncol.2019.5348

This Viewpoint discusses the potential and constraints of venture capital investment in oncology.

The Future of Cancer Care in the United States—Overcoming Workforce Capacity Limitations

Lawrence N.Shulman,MD; Lisa KennedySheldon,PhD; Edward J.Benz,MD

JAMA Oncol. 2020;6(3):327-328. doi:10.1001/jamaoncol.2019.5358

This Viewpoint discusses the challenges in providing oncologic care for an increasing number of patients and suggests potential solutions to improve clinicians’ efficiency and productivity.

Minding the Gap for Survivors of Childhood Cancer

Stephanie M.Smith,MD, MPH; Michael P.Link,MD; Karen E.Effinger,MD, MS

JAMA Oncol. 2020;6(3):330-332. doi:10.1001/jamaoncol.2019.5556

Optimizing Targeted Therapy for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Karen R.Rabin,MD, PhD

JAMA Oncol. 2020;6(3):333-334. doi:10.1001/jamaoncol.2019.5849

One Patient’s Perspective on Terminal Cancer—Sometimes It Is Best Not to See

PaulRousseau,MD

JAMA Oncol. 2020;6(3):329. doi:10.1001/jamaoncol.2019.5017

In this essay, the author details how his grandmother addressed a cancer diagnosis.

Clinical Benefit of Circulating Tumor DNA Analysis in Early-Stage Breast Cancer

GarvitChitkara,MBBS, DNB (Gen Surg); RohiniHawaldar,BSc, DCM; Rajendra A.Badwe,MS

JAMA Oncol. 2020;6(3):439. doi:10.1001/jamaoncol.2019.5677

Clinical Benefit of Circulating Tumor DNA Analysis in Follow-up of Patients With Early-Stage Breast Cancer—Reply

IsaacGarcia-Murillas,PhD, BSc; Nicholas C.Turner,MD, PhD

JAMA Oncol. 2020;6(3):439-440. doi:10.1001/jamaoncol.2019.5682

BRCA Mutations and hom*ologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab

JianzhenLin,PhD; XuYang,PhD; HaitaoZhao,MD

JAMA Oncol. 2020;6(3):440-441. doi:10.1001/jamaoncol.2019.4595

BRCA Mutations and hom*ologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab—Reply

Panagiotis A.Konstantinopoulos,MD, PhD; ShavetaVinayak,MD, MS

JAMA Oncol. 2020;6(3):441. doi:10.1001/jamaoncol.2019.4601

Lead-Time Bias in the Analyses of Overall Mortality of Breast Cancer in Men vs Women

Myvon Euler-Chelpin,PhD

JAMA Oncol. 2020;6(3):441-442. doi:10.1001/jamaoncol.2019.6286

Lead-Time Bias in the Analyses of Overall Mortality of Breast Cancer in Men vs Women—Reply

FeiWang,MD, PhD; Xiao-OuShu,MD, PhD

JAMA Oncol. 2020;6(3):442. doi:10.1001/jamaoncol.2019.6298

Association of Early Palliative Care With Survival in Patients With Advanced Lung Cancer

MarkoSkelin,MPharm, PhD; EugenJavor,MPharm; MarkoLucijanic,MD, PhD

JAMA Oncol. 2020;6(3):442-443. doi:10.1001/jamaoncol.2019.6295

Association of Early Palliative Care With Survival in Patients With Advanced Lung Cancer—Reply

Donald R.Sullivan,MD, MA, MCR; Christopher G.Slatore,MD, MS

JAMA Oncol. 2020;6(3):443-444. doi:10.1001/jamaoncol.2019.6301

Errors in Coauthors’ Names and Affiliation, Table Data, Figure Data, and Supplement

free access

JAMA Oncol. 2020;6(3):444. doi:10.1001/jamaoncol.2020.0224

Error in Figure

free access

JAMA Oncol. 2020;6(3):444. doi:10.1001/jamaoncol.2020.0230

Error in Institution Name in the Text

free access

JAMA Oncol. 2020;6(3):444. doi:10.1001/jamaoncol.2020.0360

JAMA Oncology

free access

JAMA Oncol. 2020;6(3):315. doi:10.1001/jamaoncol.2019.4209

• 36,966 Views

  Benign vs Malignant Tumors

• 13,995 Views

  Global Burden of Cancer, 2010 to 2019

• 7,474 Views

  Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Lung Cancer

• 7,473 Views

  Ascites, or Fluid in the Belly, in Patients With Cancer

• 6,262 Views

  Sentinel Lymph Node Biopsy vs No Axillary Procedure in Small Node-Negative Breast Cancer

• 5,260 Views

  Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer

• 5,195 Views

  Global Burden of Cancer, 1990 to 2017

• 5,176 Views

  Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer

• 3,292 Views

  Neoadjuvant Chemoimmunotherapy for NSCLC

• 3,184 Views

  Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer

View more >

• 715 Citations

  Global Burden of Cancer, 2010 to 2019

• 212 Citations

  Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer

• 206 Citations

  Efficacy of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

• 203 Citations

  Seropositivity Following mRNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

• 196 Citations

  Geriatric Assessment–Driven Intervention and Chemotherapy Toxic Effects in Older Adults With Cancer

• 171 Citations

  Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic NSCLC

• 159 Citations

  Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue

• 149 Citations

  Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection

• 145 Citations

  Association of DCVax-L With Extension of Survival Among Patients With Glioblastoma

• 133 Citations

  Chemoradiotherapy Plus Induction or Consolidation Chemotherapy for Locally Advanced Rectal Cancer

View more >